vor 2 Jahren

Life Sciences Report 2017 / 2018

  • Text
  • Technology
  • Medicine
  • Pharma
  • Berlin
  • Innovative
  • Clinical
  • Sciences
  • Solutions
  • Pharmaceutical
  • Biotech
  • Diagnostics

20 Life

20 Life Sciences Report – Drug Discovery and Development © private “One of our main working areas is developing and manufacturing drug coated catheters and stents. InnoRa is also a service provider offering a broad range of services in the field of drug development, such as analytical chemistry, drug formulation, stability testing, sterilization, and in vitro and in vivo testing of relevant pharmaceutical properties, pharmacokinetics, efficacy, and tolerance. The Network ‘NetPhaSol’ is the perfect platform for us to meet new cooperation partners and work together to establish new products and services” Dr. Melanie Herse-Näther InnoRa GmbH Charité together with the MDC combine their strengths in the Berlin Institute of Health (BIH). The guiding principle is translational research combined with the interdisciplinary approach of systems medicine to bridge the gap between basic research and clinical applications. The “Network for Pharma Solutions“ (Net PhaSol),” launched in May of 2017, is a cooperation between over 40 companies and scientific institutions focused on the topic of “drug discovery & development.” The network, which is funded by the Federal Ministry of Economics and Energy as part of the “Central Mid-Sized Innovation Program” (ZIM), is working to establish itself as a platform for researching, developing, and marketing new products, procedures, and services in pharmaceutical development. Its primary focus is on the early stages of value chain in the drug discovery cycle, although later stages of development are not excluded. The network functions as a unit, and with an attractive portfolio of services in the areas of drug discovery, target validation, lead optimization, and drug targeting offers potential customers, partners, investors, and others diverse ways to participate and cooperate. The portfolio of services not only reflects development and marketing for the network’s own products and services, but is also intended to be attractive to potential customers for contract research and development. Networks for drug discovery and development The network “glyconet Berlin-Brandenburg (BB)” is a cooperation of over 20 companies and research institutions aimed at promoting innovative research approaches in glycobiotechnology. The network focuses on developing new synthetic, diagnostic, analytic, and therapeutic processes and systems for medicine and materials, engineering, energy, and life sciences. The goal of the glyconet BB network is to strengthen regional expertise in these areas and make that expertise visible. The glyconet BB network does this by combining member expertise, technologies, and strategies and by attending international conferences and exhibitions. The network offers players a platform to develop together innovative products based on newest developments in glycobiotechnology. Both networks are not limited to the Berlin-Brandenburg region, but are also open to national and international partners and projects. CANCER-ID is a European consortium funded by the Innovative Medicines Initiative (IMI) which currently has 36 partners from 13 countries working to establish standard protocols for and clinical validations of blood-based biomarkers. Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free tumor DNA (cfDNA), and microRNAs (miRNAs) are potential indicators for the tumor burdens of patients living with cancer. Deriving these markers from blood may offer an additional and invaluable tool for modern cancer therapy. The consortium brings together experts from academic and clinical research, innovative small-to-medium sized enterprises (SMEs), diagnostics companies, and the pharmaceutical industry, providing a unique setting to establish the clinical utility of “liquid biopsies.” In addition to Bayer as a coordinator of the project, the two biotech companies Gilupi and Alacris and the scientific institutions Max Planck Institute for Molecular Genetics and Charité - Universitätsmedizin Berlin from the German capital region are also partners in the project.

( © Roche Penzberg) vfa bio represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies (vfa). vfa campaigns for the interests of 43 worldwide leading pharmaceutical companies in the fields of health, research and economy. vfa bio seeks to exploit the therapeutic and economic potential of biotechnology to make Germany the leading biotech location in Europe. Medical biotechnology is our topic. Consequently, we primarily deal with • Medical progress provided by biopharmaceuticals - relevance, benefit and value for patients, physicians and society as a whole • Access to biopharmaceuticals for patients • Business location Germany and regulatory and economic framework for research, development and production of biopharmaceuticals • Biosimilars • Orphan Drugs

Publications in English

Publikationen auf deutsch

Clusterreport Verkehr, Mobilität und Logistik
Automotive in der Hauptstadtregion Berlin-Brandenburg
Aerospace Industrie
Biotech- und Pharmaindustrie
Forschung für die Gesundheit
Gesundheitsversorgung und Prävention
Potenzialstudie Medizintourismus Berlin-Brandenburg_2015
Clusterbroschuere Gesundheitswirtschaft
Prävention und Gesundheitsförderung
Rehabilitation in Berlin und Brandenburg
Games Industrie in der Hauptstadtregion Berlin-Brandenburg
Digitale Wirtschaft in Berlin
Fernsehen in der Hauptstadtregion Berlin-Brandenburg
Fashion in Berlin
Best Practice Wireless in der Hauptstadtregion Berlin-Brandenburg
Medien und Kreativwirtschaft in Berlin-Brandenburg
Turbomaschinen und Kraftwerkstechnik
Energienetze und -speicher in der Hauptstadtregion Berlin-Brandenburg
Kreislaufwirtschaft in Berlin
Wasserwirtschaft in Berlin
Energietechnik in der Hauptstadtregion Berlin-Brandenburg
Inkubationsprogramme in der Energiewirtschaft
Service Packages für Unternehmen in Berlin
Unternehmensservice in den Berliner Bezirken
Berlin Partner: Unser Service fuer Sie